| Literature DB >> 33235400 |
Nikiforos Alygizakis1, Athina N Markou1, Nikolaos I Rousis1, Aikaterini Galani1, Margaritis Avgeris2, Panagiotis G Adamopoulos3, Andreas Scorilas3, Evi S Lianidou1, Dimitrios Paraskevis4, Soritios Tsiodras5, Athanassios Tsakris6, Meletios-Athanasios Dimopoulos7, Nikolaos S Thomaidis1.
Abstract
In March 2020 the World Health Organization announced a pandemic outbreak. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen for the coronavirus disease-19 (COVID-19) pandemic. The authorities worldwide use clinical science to identify infected people, but this approach is not able to track all symptomatic and asymptomatic cases due to limited sampling capacity of the testing laboratories. This drawback is eliminated by the Wastewater-Based Epidemiology (WBE) approach. In this review, we summarized the peer-reviewed published literature (available as of 28th September 2020), in the field of WBE. The commonly used steps (sampling, storage, concentration, isolation, detection) of the analytical protocols were identified. The potential limitations of each stage of the protocols and good practices were discussed. Finally, new methods for the efficient detection of SARS-CoV-2 were proposed.Entities:
Keywords: COVID-19 pandemic; RT-qPCR; concentration; influent wastewater; isolation; molecular methods detection; sampling; symptomatic and asymptomatic; temperature storage; wastewater-based epidemiology
Year: 2020 PMID: 33235400 PMCID: PMC7677696 DOI: 10.1016/j.trac.2020.116125
Source DB: PubMed Journal: Trends Analyt Chem ISSN: 0165-9936 Impact factor: 12.296
Reviewed studies of the five steps of analysis.
| Sampling | Analysis Volume | Storage conditions | Concentration | Isolation | Detection | External Control | Recovery (%) | Cq | Ref |
|---|---|---|---|---|---|---|---|---|---|
| 100–200 mL | 4°C for 24 h | Adsorption-extraction (pH = 4; neutral pH; 25 mM MgCl2) Centrifugal filter (Amicon ultra-15 (30 K); Centricon Plus-70) Polyethylene glycol (PEG 8000) precipitation Ultracentrifugation | RNeasy PowerMicrobiome Kit (slightly modified) | TaqMan-based RT-qPCR | Oncorhynchus keta (PCR inhibitors) | NA | 19-120 copies/L | [ | |
| Cq: 37.5–39 | |||||||||
| 50 mL | 4°C | Electronegative membranes Ultrafiltration | Combination of two kits (RNeasy PowerWater Kit and RNeasy PowerMicrobiome Kit) | RT-qPCR; Target sequencing (Illumina and Sanger) | Murine hepatitis virus (Recovery) | 26.7–65.7 | NA | [ | |
| Oncorhynchus keta (PCR inhibitors) | |||||||||
| Weekly pooled 24 h and grab | 125 mL (Innovaprep) | Immediately concentrated | InnovaPrep Concentrating Pipette Select Electronegative filtration | Armored RNA Quant (protocol B 2.0.1 with modifications) | Reverse transcription droplet digital PCR (RT-ddPCR) | Bovine coronavirus (BCoV) (Recovery) | 45–73 (no conc, BCoV) 62–88 (no conc, BRSV) 3.1–7.6 (Innovaprep, BCoV) 4.6–10.6 ((Innovaprep, BRSV) 2.0–7.6 (electronegative filtration, BCoV) 2.8–10.4 (electronegative filtration, BRSV) | 102-105 copies/L | [ |
| Bovine respiratory syncytial virus (BRSV) (Recovery) | |||||||||
| Hep G Armored | |||||||||
| RNA (PCR inhibitors) | |||||||||
| 200–5000 mL | Immediately analyzed | Electronegative membrane-vortex Filtration with mixed cellulose-ester membrane | QIAamp Viral RNA Mini Kit and RNeasy PowerWater Kit | RT-qPCR, Nested PCR and Direct nucleotide sequencing using the Sanger method | Coliphage MS2 | 46.4–96.8 (electronegative membrane-vortex) 4.8–12.2 (adsorption direct RNA extraction methods) | EMV method: 1.8 × 105–1.0 × 108 copies/L | [ | |
| Adsorption-direct RNA extraction method: <1.0 × 10–1.3 × 106 copies/L | |||||||||
| 50 mL | 19 days at 4°C and others Immediately analyzed | PEG 9000 | NucleoSpin® RNA Virus | TaqPath™ Covid-19 RT-PCR Kit | Coliphage MS2 | 57 (geometric mean) | 32.45-39.56 | [ | |
| 5.6 × 10 - 3.5 × 102 copies/L | |||||||||
| 250 mL | −20°C | PEG-dextran method | NucliSENS miniMAG semi-automated extraction system | Three different nested RT-PCR assays, one real-time qPCR assay and direct nucleotide sequencing using the Sanger method | Alphacoronavirus HCoV 229E | 1.34-2.74 | 102 -5.6 × 104 copies/L | [ | |
| 250 mL | 4°C for 24 h | Centricon® Plus-70 centrifugal ultrafilters | RNeasy PowerMicrobiome Kit | RT-qPCR | F-specific RNA phages Dengue virus | 8.1–52.7 (Dengue virus internal control) 23–123 (culturable F-specific RNA phages) | 2.6-2.2 × 103 copies/L | [ | |
| Cq: 29.9–39.2 | |||||||||
| 24 h composite (time or flow dependent) | 500 mL | 5 ± 3°C until analysis within 48 h | Direct flocculation | NucliSENS® miniMAG® system | EliGene COVID19 Basic A RT kit | Transmissible gastroenteritis coronavirus (TGEV) | 22.5–48.6 | Cq: 34-40 | [ |
| 200 mL | 4°C for almost two months | Aluminum-driven flocculation | Centrifugation at 1900×g for 30 min | RT-qPCR | Mengovirus vMC0 | 2.56-18.9 | Cq: 33.87–37.84 | [ | |
| 1.6–9.7 × 105 copies/L | |||||||||
| 200 mL | 4°C and concentrated within 24 h | Aluminum hydroxide adsorption-precipitation protocol | Nucleo-Spin RNA virus kit | TaqMan real-time RT-PCR | Mengovirus vMC0 | 8.9–13.1 | 6.3 × 104 -6.3 × 105 copies/L | [ | |
| Cq: 34.68–40 | |||||||||
| 50 mL | Not available | No concentration performed | QIAMP Viral RNA mini kit | RT-qPCR, whole genome sequencing and Ion Torrent PGM | Internal plasmidic control included in the 2019-nCoV real-time RT-PCR kit panel | >90 | Cq: ≤40 | [ | |
| 250 mL | −80°C until analysis and within 6 h | Ultrafiltration Centricon® Plus-70 centrifugal filter Electronegative membrane | ZR Viral RNA Kit | RT-qPCR | Pseudomonas bacteriophage Φ6 | 56 (Centricon Filter) 54 (Electronegative mebrane) | 3.1–7.5 × 103 copies/L | [ | |
| 45 mL | −18°C | Ultrafiltration | NucleoSpin RNA Virus kit | RT-qPCR and Sanger sequencing analysis | NA | NA | 30-200 gene equivalents/L | [ |
Target genes, primers and probes commonly used for analysis of SARS-CoV-2 in wastewater by PCR.
| Target | Primers and probes Sequences (5-3) | References |
|---|---|---|
| N- Sarbeco protein | F-CACATTGGCACCCGCAATC | [ |
| R-GAGGAACGAGAAGAGGCTTG | ||
| P-FAM-ACTTCCTCAAGGAACAACATTGCCA-BHQ1 | ||
| THREE regions of nucleocapsid (N) gene (CDC) | 2019-nCoV_N1–F: GAC CCC AAA ATC AGC GAA AT | [ |
| 2019-nCoV_N1-R: TCT GGT TAC TGC CAG TTG AAT CTG | ||
| 2019-nCoV_N1–P: FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1 | ||
| 2019-nCoV_N2 Forward Primer TTA CAA ACA TTG GCC GCA AA | ||
| 2019-nCoV_N2 Reverse Primer GCG CGA CAT TCC GAA GAA | ||
| 2019-nCoV_N2 Probe FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1 | ||
| 2019-nCoV_Forward Primer: AGA TTT GGA CCT GCG AGC G | ||
| 2019-nCoV_Reverse Primer: GAG CGG CTG TCT CCA CAA GT | ||
| 2019-nCoV_F Probe: FAM – TTC TGA CCT GAA GGC TCT GCG CG – BHQ-1 | ||
| ORF1ab | FW1 GTGCTAAACCACCGCCTG | [ |
| REV1 CAGATCATGGTTGCTTTGTAGGT | ||
| FW2 CGCCTGGAGATCAATTTAAACAC | ||
| REV2 ACCTGTAAAACCCCATTGTTGA | ||
| RdRP | RdRP_SARSr-F2 GTGARATGGTCATGTGTGGCGG | |
| RdRP_SARSr-R2 CARATGTTAAASACACTATTAGCATA | ||
| RdRP_SARSr-P2 FAM-CAGGTGGAACCTCATCAGGAGATGCBHQ1 | ||
| S | WuhanCoV-spk1-F: TTGGCAAAATTCAAGACTCACTTT | |
| WuhanCoV-spk2-R: TGTGGTTCATAAAAATTCCTTTGTG | ||
| Envelope protein (E) gene | E_Sarbeco_F: ACAGGTACGTTAATAGTTAATAGCGT | [ |
| E_Sarbeco_R: ATATTGCAGCAGTACGCACACA | ||
| E_Sarbeco_PROBE: FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ |